Streetbeat News

Products Services

CRM

Salesforce's Dreamforce AI conference featured comedian John Mulaney, who humorously criticized the event, AI industry, and attendees. Mulaney's remarks highlighted the irony of focusing on AI in a city with significant social issues.

Portfolio Pulse from Aaron Bry

September 24, 2024 | 8:47 pm

AMGN

Amgen reports positive results from a Phase 3 trial of TEPEZZA for chronic TED, with significant improvement in proptosis. A second trial is ongoing in Japan.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:45 pm

AMGN

Amgen's experimental drug Rocatinlimab has successfully met its primary endpoints in a late-stage study, as announced by an Amgen executive during a conference call.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:40 pm

MSGM

Motorsport Games shares rose following the release of the September Update for 'Le Mans Ultimate'.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:32 pm

MSGM

Le Mans Ultimate has introduced a new co-op game mode, a save & load system, and the 2024 Pack 2 DLC. These updates enhance the gaming experience and could attract more players.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:31 pm

CVLT

Commvault has acquired Clumio for approximately $47 million. The acquisition aims to enhance Commvault's capabilities in protecting large data sets, particularly for AI workloads, as the focus in the cyber landscape shifts towards resilience.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:29 pm

KAPA

Kairos Pharma's stock is rising following its partnership with PreCheck Health Services to develop biomarkers aimed at overcoming cancer drug resistance in prostate and lung cancer.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:28 pm

KAPA

Kairos Pharma has partnered with PreCheck Health Services to develop biomarkers aimed at targeting cancer drug resistance in prostate and lung cancer patients. This collaboration seeks to enhance patient selection for Kairos Pharma's ENV105 therapy.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:21 pm

LMT

Lockheed Martin (NYSE:LMT) has seen a surge in options activity, with significant trades indicating a mixed sentiment among big-money investors. The options activity suggests a focus on a price range between $520 and $600. Despite a slight dip in stock price, analysts maintain a bullish outlook with a target of $635.

Portfolio Pulse from Benzinga Insights

September 24, 2024 | 8:15 pm

PRZO

ParaZero Technologies shares rose following a $187K purchase order from a US-based advanced air mobility company, indicating positive market reception and potential growth in the aerial vehicle industry.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:10 pm